--- title: "Lexaria Bioscience (LEXX) news: reverse split and delisting" url: "https://aibio.space/companies/lexaria-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LEXX reverse split, delisting, going concern and offering news: Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule." --- LEXX Lexaria Bioscience Corp. NASDAQ · Canada # Lexaria Bioscience (LEXX) news LEXX reverse split, delisting and going concern news Financings · 2026-09-09 ## [Lexaria agrees to warrant inducement for approximately $5.9 million in gross proceeds](https://aibio.space/news/lexaria-agrees-warrant-inducement-approximately-5-9-million-gross/) Lexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67. ## Latest Lexaria Bioscience news 1. 2026-09-09 Financings [Lexaria agrees to warrant exercise at reduced $12.92 price, about $5.9 million](https://aibio.space/news/lexaria-agrees-warrant-exercise-reduced-12-92-price-about-5-9-million/) The warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67. 2. 2026-08-17 Listings [Lexaria Bioscience regains Nasdaq bid price compliance, hearing cancelled](https://aibio.space/news/lexaria-bioscience-regains-nasdaq-bid-price-compliance-hearing/) The Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled. 3. 2026-07-30 Listings [Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule](https://aibio.space/news/lexaria-sets-1-15-reverse-split-august-3-2026-meet-nasdaq-bid-rule/) Shares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice. 4. 2025-12-16 Financings [Lexaria closes registered direct offering and warrant placement for about $3.5 million gross](https://aibio.space/news/lexaria-closes-registered-direct-offering-warrant-placement-about-3-5/) Lexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern. ## Lexaria Bioscience at a glance - **Ticker**: LEXX - **Listing**: NASDAQ - **Country**: Canada - **Cash, May 31, 2026**: $3.6 million ### Related companies - [LSL Pharma Group](https://aibio.space/companies/lsl-pharma/) TSXV: LSL - [Cannamerica Brands](https://aibio.space/companies/cannamerica-brands/) OTC: CNNXF - [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) NASDAQ: MIST - [COSCIENS Biopharma](https://aibio.space/companies/cosciens-biopharma/) TSX: CSCI - [ZYUS Life Sciences](https://aibio.space/companies/zyus-life-sciences/) TSXV: ZYUS - [Medicure](https://aibio.space/companies/medicure/) TSXV: MPH - [Simply Solventless Concentrates](https://aibio.space/companies/simply-solventless-concentrates/) TSXV: HASH - [PharmaTher Holdings](https://aibio.space/companies/pharmather/) CSE: PHRM ### Also on NASDAQ - [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL - [PHIBRO ANIMAL HEALTH CORP](https://aibio.space/companies/phibro-animal-health/) PAHC - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) ADIL - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) FULC - [Edesa Biotech](https://aibio.space/companies/edesa-biotech/) EDSA - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) PHVS ## What Lexaria Bioscience does Lexaria Bioscience Corp. is a biotechnology company dedicated to enhancing the bioavailability of a broad range of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH combines active ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds, and it can be built into oral suspensions, tablets, capsules, foods, beverages and oral pouches. The active molecules include GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids. The company says its primary focus is pharmaceutical drug products, and it also supports licensees in integrating the technology into their own products. The therapeutic areas named include diabetes, weight loss, epilepsy, hypertension and heart disease. The company says it has been allowed or granted 56 patents worldwide. The technology dates back to a 2014 relationship with Poppy's Teas LLC, which later became Poviva Corp., a wholly owned subsidiary that is the named owner of the DehydraTECH patents. Lexaria holds an exclusive license to use the technology from Poviva. The company also has a cleared Investigational New Drug application with the FDA for a cannabinoid program in heart disease and hypertension. | Product or program | What it is | Stage | |---|---|---| | DehydraTECH | Patented drug delivery technology that improves the bioavailability of active ingredients | | | GLP-1 and GIP program | DehydraTECH formulations for diabetes and weight loss | ongoing and expanding cardiometabolic clinical research | | Cannabinoid program | DehydraTECH with cannabinoids for heart disease and hypertension | cleared IND application with the FDA | Summarised from the company's [10-K filed Nov 28, 2025](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/lxrp_10k.htm). ## Lexaria Bioscience annual financials | Line | FY ended Aug 31, 2025 | FY ended Aug 31, 2024 | |---|---|---| | Revenue | [$705,923](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | [$464,278](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | | Research and development | [$8.2 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | | Net income (loss) | [-$11.9 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | [-$5.8 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | | Cash from operations | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | [-$5.0 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | | Cash and equivalents | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001166/) | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001166/) | | Short-term investments | [$143,267](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001166/) | [$55,807](https://www.sec.gov/Archives/edgar/data/1348362/000164033425002225/) | Latest balance sheet, May 31, 2026 (10-Q): cash and equivalents $3.5 million, plus short-term investments of $142,103, $3.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lexaria Bioscience Did Lexaria Bioscience do a reverse stock split? Our latest story on this, dated Jul 30, 2026: "Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lexaria-sets-1-15-reverse-split-august-3-2026-meet-nasdaq-bid-rule/). Was Lexaria Bioscience delisted? Our latest story on this, dated Jul 30, 2026: "Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lexaria-sets-1-15-reverse-split-august-3-2026-meet-nasdaq-bid-rule/). Has Lexaria Bioscience issued a going-concern warning? Our latest story on this, dated Dec 16, 2025: "Lexaria closes registered direct offering and warrant placement for about $3.5 million gross". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lexaria-closes-registered-direct-offering-warrant-placement-about-3-5/). Has Lexaria Bioscience raised money recently? Our latest story on this, dated Dec 16, 2025: "Lexaria closes registered direct offering and warrant placement for about $3.5 million gross". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lexaria-closes-registered-direct-offering-warrant-placement-about-3-5/). What is the ticker symbol of Lexaria Bioscience? Lexaria Bioscience Corp. trades under the ticker LEXX on NASDAQ. Where is Lexaria Bioscience listed? Lexaria Bioscience Corp. is listed on NASDAQ. What is the SEC CIK of Lexaria Bioscience? The SEC Central Index Key (CIK) for Lexaria Bioscience Corp. is 1348362. Its filings are on SEC EDGAR. How many shares does Lexaria Bioscience have outstanding? 24,787,446 shares as of 2026-07-13, per the cover page of its 10-Q filed 2026-07-13. Which country or territory is Lexaria Bioscience listed under? Our directory records Lexaria Bioscience Corp. under Canada. What does Lexaria Bioscience do? Our directory classifies Lexaria Bioscience Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Lexaria Bioscience? The ISIN recorded for Lexaria Bioscience Corp. is US52886N6040. Does aibio.space cover Lexaria Bioscience? aibio.space lists Lexaria Bioscience Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lexaria Bioscience incorporated? SEC records list its state or country of incorporation as NV. What does Lexaria Bioscience develop? Lexaria Bioscience Corp. is a biotechnology company dedicated to enhancing the bioavailability of a broad range of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH combines active ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds, and it can be built into oral suspensions, tablets, capsules, foods, beverages and oral pouches. What is DehydraTECH from Lexaria Bioscience? DehydraTECH: Patented drug delivery technology that improves the bioavailability of active ingredients ## Investor discussion: Lexaria Bioscience Members talk about Lexaria Bioscience (LEXX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lexaria Bioscience, newest first. Each line links the filing it comes from. 1. 2026-10-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001610/lxrp_s3.htm) 2. 2026-09-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/lxrp_ex991.htm) 3. 2026-08-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001384/lxrp_8k.htm) 4. 2026-08-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001302/lxrp_8k.htm) 5. 2026-07-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001258/lxrp_ex991.htm) 6. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/lxrp_8k.htm) 7. 2025-10-14 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033425001839/lxrp_s1.htm) 8. 2025-09-25 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033425001717/lxrp_8k.htm) 9. 2025-02-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033425000188/lxrp_424b5.htm) 10. 2025-01-10 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1348362/000164033425000058/lxrp_10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LEXX on TradingView](https://www.tradingview.com/symbols/NASDAQ-LEXX/). ## SEC filings and registration - **SEC name**: Lexaria Bioscience Corp. - **CIK**: 1348362 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LEXX (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: August 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7 - **Phone**: 250-765-6424 - **Shares outstanding**: 24,787,446 as of 2026-07-13 (10-Q filed 2026-07-13) - **Former names**: Lexaria Corp.; LEXARIA CORP. ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001610/lxrp_s3.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/lxrp_8k.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/lxrp_8k.htm) filed 2026-09-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001384/lxrp_8k.htm) filed 2026-08-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001302/lxrp_8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001258/lxrp_8k.htm) filed 2026-07-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1348362/000164033426001166/lxrp_10q.htm) filed 2026-07-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1348362/000164033426000687/lxrp_10q.htm) filed 2026-04-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001348362), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lexaria Bioscience Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LEXX, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lexaria Bioscience Corp. - **Ticker**: LEXX - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: US52886N6040 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LEXX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lexaria-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lexaria Bioscience (LEXX) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/lexaria-bioscience/